Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous CD19-BCMA dual-target CAR T-cell therapy
- Development stage
- Phase 1
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous CD19-BCMA dual-target CAR T-cell therapy is a personalized cell-based immunotherapy developed by Beijing Boren Hospital for the treatment of relapsed or refractory autoimmune diseases. The therapy involves the genetic modification of a patient's own T cells to express chimeric antigen receptors (CARs) that target both CD19, found on B-cell lineages, and B-cell maturation antigen (BCMA), found on plasma cells and plasmablasts. Utilizing an OR gate logic, the CAR T cells are activated upon encountering either antigen, facilitating a more comprehensive depletion of pathogenic B-cell populations than single-target therapies. It is currently being investigated in Phase 1 clinical trials for conditions such as systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy.
- Other names
- Autologous CD19-BCMA dual-target CAR T-cell therapyCD19-BCMA dual-target CAR-TCD-19-BCMA dual-target CAR-TCD 19-BCMA dual-target CAR-Tautologous CD19-BCMA dual-target CAR T-cell therapy-Beijing Boren Hospital-systemic lupus erythematosus-systemic sclerosis-idiopathic inflammatory myopathy
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on Autologous CD19-BCMA dual-target CAR T-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous CD19-BCMA dual-target CAR T-cell therapy.